logo
  

Dick's Sporting Goods Q3 Profit Down; Issues Q4 EPS View - Quick Facts

Dick's Sporting Goods, Inc. (DKS) reported third-quarter GAAP net income declined slightly to $49.2 million from $50.0 million in the comparable quarter last year, while earnings per share for the latest third quarter were $0.41, up from $0.40 in the prior-year period. On average, 27 analysts polled by Thomson Reuters expected the company to report earnings of $0.41 per share for the quarter. Analysts' estimates typically exclude special items.

Net sales for the quarter grew 9.0% to around $1.53 billion, from $1.40 billion, while 22 analysts expected revenues of $1.53 billion for the quarter.

Consolidated same-store sales rose 1.1%, compared with the company's guidance of an approximate 1 to 3% increase. Same-store sales for DICK'S Sporting Goods increased 1.7%, while Golf Galaxy dropped by 8.9%.

Looking ahead to the fourth quarter of 2014, the firm currently expects consolidated earnings per share of about $1.18 to $1.28, while 26 analysts project fourth-quarter earnings of $1.21 per share.

For full-year 2014, the company now expects non-GAAP earnings per share of around $2.75 to 2.85, excluding a gain on the sale of an asset and golf restructuring charges. Analysts estimate annual earnings per share of $2.79.

Earlier, the company expected full-year 2014 non-GAAP earnings of about $2.70 to $2.85 per share.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
French drug major Sanofi reported Thursday weak profit in its first quarter, despite higher net sales. The company also maintained its fiscal 2024 outlook. Sanofi shares were gaining around 4 percent in Paris trading as well as in pre-market activity on the Nasdaq. While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
RELATED NEWS
Follow RTT